An advisory panel for the US Food and Drug Administration voted unanimously Friday that the Alzheimers drug lecanemab shows clinical benefit for the treatment of the disease, paving the way for the m… [read more]
An advisory panel for the US Food and Drug Administration voted unanimously Friday that the Alzheimers drug lecanemab shows clinical benefit for the treatment of the disease, paving the way for the m… [read more]